GLP-1 Market to Reach USD 133.92 Billion by 2034, Growing at 10.9% CAGR: Polaris Market Research

According to Polaris Market Research, the global GLP-1 market was valued at USD 52.82 billion in 2025 and is projected to reach USD 133.92 billion by 2034. The market is estimated at USD 58.48 billion in 2026 and is expected to grow at a CAGR of 10.9% during 2026–2034. Expansion is being driven by rising type 2 diabetes and obesity prevalence, broader therapeutic applications, and continued innovation in oral and long-acting GLP-1 therapies.

What Is Driving GLP-1 Market Growth?

GLP-1 therapies improve insulin secretion, help regulate blood glucose, slow gastric emptying, and reduce appetite, supporting their role in type 2 diabetes and obesity management. Commercial demand is expanding as clinical use extends into obesity, cardiovascular risk management, and other cardiometabolic applications.

Research and development is also broadening the market through next-generation formulations, oral therapies, long-acting products, and dual incretin approaches. More convenient treatment pathways can improve patient acceptance and expand access.

Key Trends Shaping the GLP-1 Industry

Long-acting GLP-1 agonists dominated in 2025 because of dosing convenience and sustained therapeutic efficacy. Oral GLP-1 therapies are expected to grow faster during 2026–2034 as demand increases for noninvasive, patient-friendly treatment options.

Obesity held the largest share by target indication in 2025, supported by growing clinical acceptance and regulatory approvals. Biologics are expected to record substantial growth, reflecting strong clinical performance and extended half-life characteristics.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/glp-1-market

Market Segmentation: Drug Type, Administration, Indication and Molecule

Polaris analyzes the market by type of GLP-1 agonist drug, route of administration, target indication, molecule type, and region. These segments capture the shift toward longer-acting products, oral delivery, obesity-focused treatment, and biologic innovation.

The segmentation also helps pharmaceutical companies and healthcare stakeholders assess where treatment convenience, clinical performance, regulatory approvals, and expanding therapeutic use are shaping demand.

Regional Outlook: North America Leads and Asia Pacific Is Fastest Growing

North America dominated global revenue in 2025, supported by high disease prevalence, advanced healthcare infrastructure, early access to therapies, and established clinical adoption.

Asia Pacific is projected to record the highest growth rate during the forecast period as lifestyle-related diseases rise and healthcare access improves. Expanding diagnosis, treatment availability, and chronic-disease management programs support long-term demand.

Competitive Landscape: Leading GLP-1 Companies

Key companies identified by Polaris include Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca, Roche, Sanofi, Boehringer Ingelheim, and Tonghua Dongbao Pharmaceutical. Competition is shaped by formulation innovation, expanded indications, manufacturing capacity, clinical development, and efforts to improve treatment convenience and accessibility.

More Trending Latest Reports By Polaris Market Research:

Drug Delivery Market

Carbon Accounting Software Market

Thyroid Cancer Diagnostics Market

Cell & Gene Therapy Bioanalytical Testing Services Market

Carbon Accounting Software Market

Platelet Rich Plasma (PRP) Market

Meniscus Repair Systems Market

A Rise in Therapeutic Benefit from Phytosterols to Drive Significant Market Growth

Pizza Oven Market